References
- Phillips SJ, Whisnant JP, O’Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin. Proc. 65(3), 344–359 (1990).
- Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303(20), 2043–2050 (2010).
- Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol. 104(11), 1534–1539 (2009).
- Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18), 2370–2375 (2001).
- Vardas P, Marakis H. Atrial fibrillation and heart failure. Hellenic J. Cardiol. 45, 277–281 (2004).
- Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am. J. Cardiol. 91(10A), 9G–14G (2003).
- Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271(11), 840–844 (1994).
- Connolly SJ, Eikelboom J, Joyner C et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364(9), 806–817 (2011).
- Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883–891 (2011).
- Wong ND, Lopez VA, L’Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch. Intern. Med. 167(22), 2431–2436 (2007).
- Sciarretta S, Pontremoli R, Rosei EA et al. Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on Microalbuminuria in patients with hypertensive Disease study. J. Hypertens. 27(2), 410–417 (2009).
- Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 91(1), 265–325 (2011).
- Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace 10(2), 238–241 (2008).
- Saygili E, Rana OR, Saygili E et al. Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes. Am. J. Physiol. Heart Circ. Physiol. 292(6), H2898–H2905 (2007).
- Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am. J. Geriatr. Cardiol. 14(2), 56–61 (2005).
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8), 983–988 (1991).
- Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotics therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449–1457 (1994).
- Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al.; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31, 2369–2429 (2010).
- Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L et al.; GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 360, 1606–1617 (2009).
- Naccarelli GV, Peacock F. Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation. Vasc. Health Risk Manag. 5, 783–791 (2009).